Clin Endosc.
2023 Jul;56(4):453-454. 10.5946/ce.2023.133.
Improving the quality of the esophagogastroduodenoscopy in Helicobacter pylori-naïve gastric cancer
- Affiliations
-
- 1Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
- KMID: 2544566
- DOI: http://doi.org/10.5946/ce.2023.133
Reference
-
1. Kim SY, Park JM. Quality indicators in esophagogastroduodenoscopy. Clin Endosc. 2022; 55:319–331.2. Mi EZ, Mi EZ, di Pietro M, et al. Comparative study of endoscopic surveillance in hereditary diffuse gastric cancer according to CDH1 mutation status. Gastrointest Endosc. 2018; 87:408–418.3. Ueyama H, Yao T, Nakashima Y, et al. Gastric adenocarcinoma of fundic gland type (chief cell predominant type): proposal for a new entity of gastric adenocarcinoma. Am J Surg Pathol. 2010; 34:609–619.4. Ishibashi F, Hirasawa T, Ueyama H, Minato Y, Suzuki S. Exploring quality indicators for the detection of Helicobacter pylori-naïve gastric cancer: a cross-sectional nationwide survey. Clin Endosc. 2023; 56:460–469.5. Park JM, Huo SM, Lee HH, Lee BI, Song HJ, Choi MG. Longer observation time increases proportion of neoplasms detected by esophagogastroduodenoscopy. Gastroenterology. 2017; 153:460–469.
